🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "significant breakthrough" in the battle against superbug strains of the infection, according to health experts.

A Global Health Concern

Gonorrhoea infections are on the rise worldwide, with estimates suggesting in excess of 82 million instances each year. Particularly high rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune development in the face of rising global incidence, increasing antimicrobial resistance and the highly restricted therapeutic options at this time.”

Health officials are deeply concerned about the increase in drug-resistant strains. The World Health Organization has listed it as a "priority pathogen". Recent surveillance found that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Gain Clearance

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the American regulatory agency in December for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers believe that targeted use of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the drugmaker GSK, also received approval in close succession. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This milestone marks a significant shift in the management of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Testing Results and Global Access

As per results detailed in a prominent scientific publication, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This places it at an similar efficacy with the current standard treatment, which combines two antibiotics. The study enrolled over 900 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals directly involved have expressed optimism. Access to a one-pill regimen of this kind is hailed as a "critical tool" for gonorrhoea control. This is viewed as vital to reduce the burden of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea globally.